CytomX Therapeutics Surges on Promising Early Colorectal Cancer Data, Analysts Bullish on Probody Platform
Shares of CytomX Therapeutics (CTMX) jumped over 14% this week after early-stage clinical data for its lead Probody candidate, varsetatug maseatecan, in metastatic colorectal cancer drew positive reactions from Wall Street. The move highlights growing confidence in the company's conditionally activated antibody platform, designed to target tumors more precisely while sparing healthy tissue.